Introduction
Summary: Healthcare AI can create privacy risks as sensitive information moves through systems and organizations. Data, technical, organizational, and regulatory safeguards can reduce those risks, but organizations should verify which requirements apply to their deployment and jurisdiction.
Artificial intelligence privacy in healthcare matters because AI systems may process information about diagnoses, treatment, medications, and other sensitive aspects of a person’s life. Data can pass through multiple stages and organizations, creating privacy risks if collection, access, use, or retention is not properly managed. Those risks can be reduced through safeguards, but no single technical control or contract makes every deployment safe or compliant.
This guide explains how health information may move through an AI system, where privacy risks can arise, and what organizations should check when selecting and overseeing safeguards. It also outlines regulatory considerations, with the United States as the primary reference. Requirements depend on the organization, data, activity, and jurisdiction, so this is general educational information, not legal or clinical advice. Organizations should obtain current legal review before deployment.
How AI Uses Health Information
A healthcare AI data flow can begin when an organization collects records, images, measurements, or text for a defined task.
Data may then be cleaned, labeled, combined, or otherwise prepared before being used to train or configure a model. Once deployed, a system may process new inputs and produce outputs. Information can also be stored in application logs, cloud services, or other systems, shared with vendors, and eventually deleted according to applicable requirements and organizational decisions.
For example, a clinic might send appointment notes to an AI service to generate draft summaries. In this hypothetical flow, the clinic, service provider, and any cloud or application partners may handle different parts of the information. The organization would need to map those flows and establish what each party can access and retain.
Health information may be directly identifiable, or it may be de-identified or aggregated. These labels are not interchangeable: aggregation describes combining information, while de-identification concerns reducing the risk of identifying a person. Under HIPAA, HHS describes two methods for de-identification, Expert Determination and Safe Harbor. Information properly de-identified under HIPAA is not protected health information under that law, but the classification depends on meeting its standard and does not establish that every inference or linkage risk is eliminated. HHS explains HIPAA de-identification methods.
When vendors create, receive, maintain, or transmit protected health information for a healthcare entity, business-associate arrangements with written privacy and security assurances may be required. Whether that applies depends on the parties, data, and services. A contract is important, but does not by itself demonstrate that safeguards work. HHS describes business-associate relationships.
Key Privacy Risks of AI in Healthcare
Privacy risks can arise at any stage of an AI deployment. Unauthorized access or a security incident could expose information held by a healthcare organization or one of its service providers. Collecting more data than a task requires, retaining it longer than intended, or failing to limit access can increase exposure. These are risks to assess, not evidence that every AI system has experienced a breach.
Secondary use is another concern. Data collected for one purpose might be reused for model development, analytics, or another service. Organizations should not assume that a vendor uses prompts for training, retains them for a particular period, or shares them with subcontractors. Practices vary by product, configuration, contract, and jurisdiction, and must be checked directly.
The distinction between model training and operational retention is important. Microsoft states that Azure OpenAI prompts and generations are not used to train, retrain, or improve its base models. Its documentation also says that prompts and generated content may be stored securely for up to 30 days for abuse detection and mitigation. These are first-party statements about the cited service, not evidence about all vendors or every deployment. Organizations should confirm the applicable product, settings, logging, terms, and retention practices. Microsoft documents Azure OpenAI data handling.
AI systems can also create leakage or unauthorized disclosure risks through inputs and outputs. NIST’s generative AI risk-management profile identifies privacy impacts that include leakage, unauthorized use or disclosure, and de-anonymization of sensitive information. It describes risk categories, not proof that a particular healthcare system has suffered an incident. NIST’s profile outlines generative AI risks.
De-identification can reduce risk when the relevant standard is satisfied, but it should not be treated as a guarantee against all inference or linkage. Risk depends on the information, context, and safeguards. Finally, unclear data flows can make it difficult to determine who is responsible for access requests, correction, deletion, or consent-related processes. That is a governance and privacy concern, distinct from broader questions of clinical safety or model bias.
Privacy Rules and Responsibilities to Check
In the United States, HIPAA does not automatically cover every organization that handles health-related information or uses AI. It applies to defined covered entities, including health plans, healthcare clearinghouses, and qualifying healthcare providers. Start by identifying the organization, its activities, the information involved, and whether the organization is a covered entity under HHS’s HIPAA overview.
An AI vendor may also be a business associate if it performs services for a covered entity that involve protected health information. Covered entities generally need written business associate agreements with qualifying vendors, and business associates have direct responsibility for certain HIPAA requirements. But the vendor’s role depends on its actual services, access, and data flows, not simply its product label. Review HHS’s business associate guidance and the relevant facts.
Other U.S. rules may apply. The FTC Health Breach Notification Rule, for example, can cover certain personal-health-record vendors and related entities, including some outside HIPAA, when a qualifying breach involves unsecured health information. Its application depends on the product and circumstances. State privacy requirements also vary. As one specific example, California amended a CCPA provision concerning correction requests for health-related personal information, with the amendment effective January 1, 2026. That does not establish a nationwide rule or mean the CCPA applies to every healthcare AI provider; check the conditions and exemptions in the California statute.
For processing within the GDPR’s territorial scope, health data are special-category data. Organizations generally need both an Article 6 lawful basis and an applicable Article 9 condition; AI use alone is not a basis. Controller and processor roles depend on actual processing purposes and means, not just contract labels. Other EU and national requirements may also matter. See the GDPR text.
The EU AI Act has staged dates: Article 50 transparency requirements begin August 2, 2026, while specified high-risk system obligations have later dates, including December 2, 2027, and August 2, 2028. The system’s category and applicable timeline need assessment. See the EU AI Act implementation timeline. The rules depend on the organization, data, AI use, and jurisdictions involved. Do not assume every health-related app or AI provider is covered by HIPAA. Seek current legal review before deployment; this overview is educational, not legal advice.
Safeguards That Reduce Privacy Risk
Safeguards work best as a coordinated set, rather than a promise that any one control will eliminate privacy risk. Begin with the data: document what the AI system receives, why each field is needed, where it goes, who can access it, and how long it is kept. Avoid collecting or retaining information without a defined purpose. Where appropriate, assess whether data can be de-identified. For HIPAA information, HHS describes two recognized methods, Expert Determination and Safe Harbor; do not treat an informal removal of names as proof of de-identification.
Assess security and privacy risks before deployment, then revisit the assessment when data flows, features, or vendors change. For electronic protected health information, HHS risk-analysis guidance calls for assessing risks and vulnerabilities affecting confidentiality, integrity, and availability. Organizations can consider controls such as limiting access to authorized users, authentication, secure processing environments, logging, and incident-response procedures. Select and test controls for the specific system and data; their presence alone does not establish effectiveness or compliance.
Review vendors before sharing information. Check current product documentation, configuration, contract, and data-processing terms for retention periods, deletion, model-training use, abuse monitoring, geography, enabled features, subcontractors, and customer-side logs. These are separate data pathways: a statement about model training or stateless model behavior does not necessarily resolve service-level retention or storage in connected applications. NIST recommends including privacy and security risks in generative-AI procurement due diligence. Treat vendor statements as claims to verify, not independent proof. Where HIPAA applies, determine whether a business associate relationship and written agreement are required; a contract does not by itself show safeguards are effective.
| Privacy risk | Relevant safeguard | Limitation or follow-up |
|---|---|---|
| Unnecessary or excessive data use | Minimize collection and retention; assess de-identification where suitable | De-identification is not an informal label; use an appropriate method for the context |
| Unauthorized access or disclosure | Restrict access, assess security risks, and prepare incident procedures | Controls need testing and ongoing review |
| Unexpected vendor retention, training use, or sharing | Review product settings, documentation, contracts, and subprocessors | Verify current terms for the exact service and configuration |
| Changes in data flows or system features | Document decisions and reassess periodically | Safeguards do not replace legal, contractual, organizational, or human oversight |
A Practical Governance Checklist for Organizations
A structured review can help organizations identify privacy issues before an AI system handles health information. Use this checklist as a starting point, not as a substitute for legal, privacy, security, or clinical review where relevant.
-
Map the deployment. Document what data the system receives, its purpose, who uses it, where outputs go, and which vendors or subcontractors may handle the information. Identify the jurisdictions involved and the organization’s role in each processing activity.
-
Assess necessity and authority. Record why each data element is needed and what legal authority or other basis applies. Document any required privacy assessment, consent approach, retention period, and deletion decision. Treat de-identification as a matter to assess, not a label that automatically settles privacy risk.
-
Review risks and controls. For systems involving electronic protected health information, HHS guidance calls for risk analysis addressing threats to confidentiality, integrity, and availability. That is a HIPAA-focused requirement, not a single AI-specific assessment method. NIST’s generative AI profile can help identify privacy risks and inform procurement due diligence, but its recommendations are not universal legal mandates.
-
Examine vendors and data pathways. Determine whether a vendor’s role and services require a business-associate arrangement; applicability depends on the facts. Review current product terms and configuration directly. Ask about prompt retention, training use, deletion, geographic processing, subprocessors, stateful features, abuse monitoring, and application-side logs. A contract or vendor statement alone does not prove safeguards are effective. For example, Azure OpenAI documentation distinguishes model-level handling from service-level retention and other storage, so confirm the terms for the specific product and deployment.
-
Assign ownership and revisit. Name accountable owners for approval, access, monitoring, incident escalation, and periodic reassessment. Update the review when data flows, features, vendors, or applicable rules change. Not every item above is a specific legal requirement; some are prudent governance practices that help make risks and decisions visible.
For applicable HIPAA risk-analysis expectations, consult HHS guidance.
Conclusion
Healthcare AI privacy depends on managing information throughout its lifecycle, not on relying on one technical control or a label such as “de-identified.” Data can move through applications, vendors, logs, and other systems, so organizations need to understand those pathways and how each party handles the information.
Before deployment, map the data flows, confirm which legal obligations apply in each relevant jurisdiction, and review vendor terms, configurations, access, retention, and oversight. Reassess when the system, its features, or the rules change. Keep a record of decisions, assign owners for follow-up, and check that safeguards remain appropriate as workflows, vendors, data sources, and intended uses evolve. These steps support responsible decisions, but they do not replace qualified legal, privacy, security, or clinical review where needed.
For ongoing AI and technology updates, subscribe free to The Deep View Newsletter.
Summary
Healthcare AI can handle sensitive information across models, applications, vendors, and logs, creating privacy risks at multiple stages. Learn how data flows, which U.S. and other regulatory considerations to check, and how organizations can assess safeguards, vendors, and ongoing governance.